Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Diarrhea 1

Interventions

Irinotecan 4Octreotide 3Probiotics 2Leucovorin 2Fluorouracil 2shosaiko-to 1maltodextrin 1lanreotide 1isatuximab 1bile acid binding proteins 1Temozolomide 1Sulfasalazine 1Raloxifene Hydrochloride 1Radiation 1Oxaliplatin 1Loperamide 1Long-Term Synaptic Depression 1Levofloxacin 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Diet Therapy 1Cyclophosphamide 1Colesevelam Hydrochloride 1Celecoxib 1Cefpodoxime 1Cefixime 1Calcium Aluminosilicate 1Anti-Bacterial Agents 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Diarrhea × Colesevelam Hydrochloride × Clear all
NCT03767257 2025-10-21

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
25 enrolled 6 charts
Plasma cell

Diarrhea, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡